- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05634499
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA)
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Reference Study ID Number: CO44195 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. Only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
Montreal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Centre - Glen Site
-
-
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Recruiting
- Istituto Tumori Napoli;Unità Operativa Oncologia Medica Uro-Ginecologica
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italy, 47014
- Recruiting
- Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
-
-
Lazio
-
Rome, Lazio, Italy, 00168
- Recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
-
Gliwice, Poland, 44-101
- Recruiting
- Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; III Klin. Radioter. i Chemioter.
-
Kielce, Poland, 25-734
- Recruiting
- Swietokrzyskie Centrum Onkologii; Klinika Ginekologii
-
Warszawa, Poland, 02-781
- Recruiting
- Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie;Klinika Ginekologii Onkologicznej
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85710
- Recruiting
- Arizona Oncology - HOPE Wilmot
-
-
Florida
-
Miami Beach, Florida, United States, 33140
- Active, not recruiting
- Mount Sinai Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Recruiting
- Minnesota Oncology Minneapolis
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Recruiting
- Nebraska Methodist Hospital
-
-
New Jersey
-
Englewood, New Jersey, United States, 07631
- Active, not recruiting
- Englewood Health/Hematology Oncology Practice of Englewood (HOPE)
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Portland Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Western Pennsylvania Hospital
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- Texas Oncology Cancer Center
-
Fort Worth, Texas, United States, 76104
- Recruiting
- Texas Oncology, P.A. - Fort Worth
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Recruiting
- Virginia Oncology Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed Grade 1 endometrial cancer (EC) of endometrioid histology for which participants are willing to receive 6-cycles of study therapy. An endometrial biopsy (EMB) or dilation and curettage (D&C) fresh collected within the screening period or archival sample collected within 3 months prior to screening must be provided to a central laboratory for histologic confirmation to determine eligibility.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Magnetic resonance imaging (MRI)-confirmation of non-deeply invasive tumor (<50% myometrial invasion)
- MRI or computed tomography (CT)-confirmation of no extrauterine disease
- Willing to undergo a minimum of 6 continuous cycles of therapy before decision on surgery
- No prior treatment for endometrial cancer
- Able and willing to take oral medications
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- Adequate hematologic and end-organ function, as defined in the protocol
- Negative HIV test at screening, with the following exception: Patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count ≥200/μL, and have an undetectable viral load.
- For female participants of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 30 days after the final dose of giredestrant, as defined in the protocol
Exclusion Criteria:
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 30 days after the final dose of giredestrant or within the time period specified per local prescribing guidelines after the final dose of the investigator's choice of endocrine therapy
- Participants with non-endometrioid histologies, such as serous, clear cell, and mixed
- Treatment with investigational therapy within 28 days prior to initiation of study enrollment
- Treatment for cancer including but not limited to, chemotherapy, immunotherapy, cyclin-dependent kinase (CDK)4/6 inhibitors, endocrine therapy, biologic therapy, or herbal therapy within 28 days prior to the initiation of study enrollment
- Any gastrointestinal condition causing malabsorption or obstruction (e.g., celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome)
- Known hypersensitivity to giredestrant or its excipients
- Known intercurrent illness or psychiatric illness/social situations that will limit compliance with study requirements
- Evidence or high suspicion of metastatic/extrauterine disease at enrollment
- Unwilling or unable to comply with study-related procedures, including all endometrial sampling/biopsies
- Planned surgery, either for the treatment of cancer or any other surgery, during the study treatment period and up to 10 days after the completion of study treatment
- Serious infections requiring IV antibiotics within 7 days prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact participant safety
- Participants who have clinically significant liver disease consistent with Child-Pugh Class B or C, including active hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]), current alcohol abuse, cirrhosis, or positive test for viral hepatitis, as defined in the protocol
- Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study treatment
- Any serious medical condition or abnormality in clinical laboratory tests that precludes the participant's safe participation in and completion of the study
- History of other malignancy within 5 years prior to screening, except for those with an expected negligible risk for metastases or death (e.g., 5-year overall survival 90%) after curative treatment
- Active tuberculosis
- Severe infection per investigator judgment at the time of enrollment, including but not limited to, use of systemic antibiotics, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion of the investigator, could impact participant safety
- Significant cardiovascular disease, such as cardiac disease New York Heart Association Class II or greater, myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- Active cardiac disease or history of cardiac dysfunction, as defined in the protocol
- Major surgical procedure other than for diagnosis within 28 days prior to enrollment or anticipation of need for a major surgical procedure during the study
- Prior allogeneic bone marrow transplantation or solid organ transplant
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the participant at high risk for treatment complications illnesses or conditions that interfere with the participant's capacity to understand, follow, and/or comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Giredestrant
|
Participants will receive giredestrant 30 milligrams (mg) taken orally (PO) once a day (QD) on Days 1 to 28 of each 28-day cycle for 6 cycles.
After completion of 6 cycles, the participant and investigator can choose to continue study treatment for an additional 18 cycles or discontinue study treatment and receive investigator-determined care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with at Least One Adverse Event, with Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)
Time Frame: From Baseline until 30 days after the final dose of study drug (up to 1 year, 6 months)
|
From Baseline until 30 days after the final dose of study drug (up to 1 year, 6 months)
|
|
Percentage of Participants Who Have Regression at 6 Months
Time Frame: Baseline, 6 Months
|
The percentage of participants who have regression is defined as participants who have a decrease in the proportion of cancer in their endometrial biopsy or the proportion of cancer is not increased, but there is an increase in non-cancer/non-atypical hyperplasia at the 6-month assessment compared with baseline.
|
Baseline, 6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Concentration of Giredestrant at Specified Timepoints
Time Frame: Predose on Day 1 of Cycles 1, 2, 3, 4, and 6; 3-4 hours Postdose on Day 1 of Cycles 1 and 2 (each cycle is 28 days)
|
Predose on Day 1 of Cycles 1, 2, 3, 4, and 6; 3-4 hours Postdose on Day 1 of Cycles 1 and 2 (each cycle is 28 days)
|
|
Percentage of Participants Who Have Complete Regression at 6 Months
Time Frame: Baseline, 6 Months
|
The percentage of participants who have complete regression is defined as participants having an assessment of 100% of non-cancer/non-atypical hyperplasia at the Month 6 assessment.
|
Baseline, 6 Months
|
Median Duration of Regression
Time Frame: From first regression to first relapse (up to 1 year, 6 months)
|
From first regression to first relapse (up to 1 year, 6 months)
|
|
Median Time to First Regression
Time Frame: From first study treatment to first regression (up to 1 year, 6 months)
|
From first study treatment to first regression (up to 1 year, 6 months)
|
|
Median Time to Relapse or Loss of Clinical Benefit
Time Frame: From first study treatment to relapse or loss of clinical benefit, whichever occurs first (up to 1 year, 6 months)
|
From first study treatment to relapse or loss of clinical benefit, whichever occurs first (up to 1 year, 6 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CO44195
- 2022-002443-21 (EudraCT Number)
- 2023-504091-23-00 (Other Identifier: EU Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing/).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Masonic Cancer Center, University of MinnesotaCompletedCervical Cancer | Ovarian Cancer | Uterine Endometrial CancerUnited States
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
Clinical Trials on Giredestrant
-
Fondazione OncotechNot yet recruiting
-
Genentech, Inc.CompletedBreast CancerUnited States, Spain, Belgium, Australia, United Kingdom
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, Peru and more
-
Genentech, Inc.CompletedHealthy VolunteersUnited States
-
MedSIRNot yet recruiting
-
Austin V StoneNot yet recruitingMeniscus Lesion | Meniscus Tear | Meniscus Disorder | Meniscus; DerangementUnited States
-
Hoffmann-La RocheRecruitingEarly Breast CancerUnited States, Spain, France, Korea, Republic of, China, Italy, Taiwan, Sweden, Czechia, Hungary, Japan, Greece, Hong Kong, Ukraine, Australia, Brazil, Canada, Mexico, Belgium, Kenya, Argentina, Chile, Serbia, South Africa, Colombia, Ireland and more
-
Genentech, Inc.Active, not recruitingBreast CancerUnited States, Spain, Korea, Republic of, Australia, United Kingdom
-
Genentech, Inc.CompletedHealthy VolunteersUnited Kingdom
-
Seagen Inc.Merck Sharp & Dohme LLC; GenmabRecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Exocrine Pancreatic Cancer | Carcinoma, Squamous Cell of Head and NeckUnited States, Canada, France, Germany, Italy, Spain, United Kingdom, Puerto Rico